胃食管反流病内镜治疗的十个常见问题

Clinical Update Pub Date : 2004-10-01 DOI:10.1016/j.clinup.2004.07.001

George Triadafilopoulos MD

{"title":"胃食管反流病内镜治疗的十个常见问题","authors":"George Triadafilopoulos MD","doi":"10.1016/j.clinup.2004.07.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Commentary</h3><p><span>GERD<span> is the third most common GI disorder in the United States, affects 19 million US adults, and accounts annually for 4,590,000 outpatient visits and 96,000 hospitalizations, amounting to $19 billion in annual costs. The majority of patients have complete relief of symptoms on long-term medical therapy with proton pump inhibitors. However, as much as 20% continue to have a detriment in quality of life scores caused by GERD symptoms. These refractory patients, or patients who do not want to take long-term medications, may benefit from the plethora of new </span></span>endoscopic therapies for GERD. Although long-term follow-up and sham-controlled studies are, in general, not yet available, Dr. Triadafilopoulos reviews the currently available techniques and offers a unique perspective on their potential role in GERD therapy.</p><p>Grace Elta, MD</p><p>Editor</p></div>","PeriodicalId":100280,"journal":{"name":"Clinical Update","volume":"12 2","pages":"Pages 1-4"},"PeriodicalIF":0.0000,"publicationDate":"2004-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.clinup.2004.07.001","citationCount":"2","resultStr":"{\"title\":\"Ten frequently asked questions about endoscopic therapy for gastroesophageal reflux disease\",\"authors\":\"George Triadafilopoulos MD\",\"doi\":\"10.1016/j.clinup.2004.07.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Commentary</h3><p><span>GERD<span> is the third most common GI disorder in the United States, affects 19 million US adults, and accounts annually for 4,590,000 outpatient visits and 96,000 hospitalizations, amounting to $19 billion in annual costs. The majority of patients have complete relief of symptoms on long-term medical therapy with proton pump inhibitors. However, as much as 20% continue to have a detriment in quality of life scores caused by GERD symptoms. These refractory patients, or patients who do not want to take long-term medications, may benefit from the plethora of new </span></span>endoscopic therapies for GERD. Although long-term follow-up and sham-controlled studies are, in general, not yet available, Dr. Triadafilopoulos reviews the currently available techniques and offers a unique perspective on their potential role in GERD therapy.</p><p>Grace Elta, MD</p><p>Editor</p></div>\",\"PeriodicalId\":100280,\"journal\":{\"name\":\"Clinical Update\",\"volume\":\"12 2\",\"pages\":\"Pages 1-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.clinup.2004.07.001\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1070721204000041\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Update","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1070721204000041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

摘要

评论胃食管反流是美国第三大最常见的胃肠道疾病，影响了1900万美国成年人，每年有459万门诊人次和9.6万住院人次，每年花费190亿美元。大多数患者在质子泵抑制剂的长期药物治疗下症状完全缓解。然而，仍有多达20%的患者因胃食管反流症状导致生活质量评分下降。这些难治性患者，或者不想长期服用药物的患者，可能会受益于大量新的内镜治疗胃食管反流。虽然目前还没有长期随访和假对照研究，但Triadafilopoulos博士回顾了目前可用的技术，并就其在反流治疗中的潜在作用提供了独特的观点。格蕾丝·埃尔塔，mdedeitor

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Ten frequently asked questions about endoscopic therapy for gastroesophageal reflux disease

Commentary

GERD is the third most common GI disorder in the United States, affects 19 million US adults, and accounts annually for 4,590,000 outpatient visits and 96,000 hospitalizations, amounting to $19 billion in annual costs. The majority of patients have complete relief of symptoms on long-term medical therapy with proton pump inhibitors. However, as much as 20% continue to have a detriment in quality of life scores caused by GERD symptoms. These refractory patients, or patients who do not want to take long-term medications, may benefit from the plethora of new endoscopic therapies for GERD. Although long-term follow-up and sham-controlled studies are, in general, not yet available, Dr. Triadafilopoulos reviews the currently available techniques and offers a unique perspective on their potential role in GERD therapy.

Grace Elta, MD

Editor

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助